Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Aldesleukin + Vemurafenib in Metastatic Melanoma
NCT01683188Phase 4Terminated
- Sponsor
- Clinigen
- Start
- Aug 2012
- Primary completion
- Nov 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 4 trial of aldesleukin in melanoma, sponsored by Clinigen. Started Aug 2012; status: terminated.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01683188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01683188.